Poor prognosis acute myelogenous leukemia.
Poor prognosis AML consists of 3 clinically definable groups of patients whose response to therapy is substantially worse than that of standard prognosis patients. The response rate is lowest for those patients who have more than a single risk factor and for the patients who have low platelet and serum albumin levels at diagnosis. The treatment associated mortality of the latter patients is quite high. Even if one avoids the high mortality rate by carefully selecting patients the likelihood that drug resistant disease is present is very high. Since the basis for resistance is multifactorial, a variety of strategies will have to be explored as means to improve treatment outcome. At the present time, the greatest chance for long term survival is found in relatively young patients whose AML is induced into complete remission and who then receive a matched allogeneic bone marrow transplant.
Preisler
H
H
University of Cincinatti Medical Center, Ohio 45267-0508.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000150:complications; D016026:Bone Marrow Transplantation; D002455:Cell Division / Q000187:drug effects; D003561:Cytarabine / Q000008:administration & dosage / Q000494:pharmacology; D003630:Daunorubicin / Q000008:administration & dosage / Q000494:pharmacology; D004351:Drug Resistance; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000145:classification* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D007953:Leukemia, Radiation-Induced / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000401:mortality / Q000473:pathology / Q000628:therapy; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000473:pathology; D011289:Preleukemia / Q000453:epidemiology; D011379:Prognosis; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D016879:Salvage Therapy; D016019:Survival Analysis; D017211:Treatment Failure
D011994:Recombinant Proteins; D003561:Cytarabine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003630:Daunorubicin